UCB and Amgen have announced top-line results from the STRUCTURE trial (STudy evaluating effect of RomosozUmab Compared with Teriparatide in postmenopausal women with osteoporosis at high risk for fracture previously treated with bisphosphonatE therapy). The study (NCT01796301) met the primary endpoint, demonstrating a statistically significant difference in favor of romosozumab in the percent change of total hip bone mineral density (measured by DXA) through month 12.1
STRUCTURE was a Phase 3, multi-center, international, randomized, open-label, teriparatide-controlled study that evaluated the safety, tolerability and efficacy of romosozumab in women with postmenopausal osteoporosis.
